Literature DB >> 15906273

The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?

Eberhard Korsching1, Jens Packeisen, Cornelia Liedtke, Daniela Hungermann, Pia Wülfing, Paul J van Diest, Burkhard Brandt, Werner Boecker, Horst Buerger.   

Abstract

Vimentin expression is a rather rare finding in invasive breast cancer, and is associated with high tumour invasiveness and chemoresistance. It is currently explained by two different biological theories: direct histogenetic derivation from myoepithelial cells, and epithelial-mesenchymal transition (EMT) reflecting the end-stage of breast cancer dedifferentiation. In this study we aimed to obtain further insights into the biological hallmarks of these vimentin-expressing breast cancers. We applied immunohistochemistry for vimentin and 15 other differentiation markers to a series of 364 invasive breast cancer cases, using tissue microarray technology. 7.7% of all tumours expressed vimentin. Almost all of these cases (19/21) were Grade 3 invasive ductal carcinomas, and the majority (13/21) of these were associated with a ductal in situ component. Vimentin expression was also seen in the respective in situ components and correlated positively with the expression of SMA, CD10, CK 5, p53, Mib-1 and EGFR. A negative correlation was seen for the expression of CK 8/18 and the oestrogen receptor. Vimentin-expressing carcinomas revealed a significantly higher average absolute number of cytogenetic alterations per case, but a significantly lower frequency of chromosome 16q losses compared to vimentin-negative cases. Our present results demonstrate that, despite analogies between vimentin-positive breast cancers and myoepithelial cells in their expression of differentiation-related proteins, neither myoepithelial histogenesis nor EMT can exclusively explain the biology of these distinct tumours. This is mainly supported by the significantly higher incidence of vimentin-expressing breast cancers compared to any other myoepithelial breast tumours and the fact that vimentin is already observed in ductal in situ components. We therefore propose the alternative hypothesis that vimentin-expressing breast carcinomas may derive from breast progenitor cells with bilinear (glandular and myoepithelial) differentiation potential. Copyright 2005 Pathological Society of Great Britain and Ireland

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906273     DOI: 10.1002/path.1797

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  76 in total

Review 1.  Vimentin in cancer and its potential as a molecular target for cancer therapy.

Authors:  Arun Satelli; Shulin Li
Journal:  Cell Mol Life Sci       Date:  2011-06-03       Impact factor: 9.261

Review 2.  Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer.

Authors:  Tony Blick; Honor Hugo; Edwin Widodo; Mark Waltham; Cletus Pinto; Sendurai A Mani; Robert A Weinberg; Richard M Neve; Marc E Lenburg; Erik W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-06-04       Impact factor: 2.673

Review 3.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

4.  Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response.

Authors:  N Erin; A Podnos; G Tanriover; Ö Duymuş; E Cote; I Khatri; R M Gorczynski
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

5.  Pleomorphic carcinoma of the breast in a 17-year-old woman.

Authors:  Rin Yamaguchi; Maki Tanaka; Miki Yamaguchi; Takanaru Fukushima; Yuko Kaneko; Hiroko Otsuka; Shin Isobe; Hiroshi Terasaki; Osamu Nakashima; Masayoshi Kage; Hirohisa Yano
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

6.  Correlation of Forkhead Box c2 with subtypes and invasive ability of invasive breast cancer.

Authors:  Jun Dai; Jin-Yu Wang; Li-Li Yang; Ying Xiao; Zhi-Ling Qu; Sheng-Hui Qin; Qiu-Rong Ruan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 7.  Epithelial to mesenchymal transition and breast cancer.

Authors:  Eva Tomaskovic-Crook; Erik W Thompson; Jean Paul Thiery
Journal:  Breast Cancer Res       Date:  2009-11-09       Impact factor: 6.466

8.  The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.

Authors:  Mireia Margeli; Beatriz Cirauqui; Eva Castella; Gustavo Tapia; Carlota Costa; Ana Gimenez-Capitan; Agusti Barnadas; Maria Sanchez Ronco; Susana Benlloch; Miquel Taron; Rafael Rosell
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

9.  Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry.

Authors:  Donald J Johann; Jaime Rodriguez-Canales; Sumana Mukherjee; DaRue A Prieto; Jeffrey C Hanson; Michael Emmert-Buck; Josip Blonder
Journal:  J Proteome Res       Date:  2009-05       Impact factor: 4.466

10.  Does vimentin help to delineate the so-called 'basal type breast cancer'?

Authors:  Renata U Kusinska; Radzislaw Kordek; Elzbieta Pluciennik; Andrzej K Bednarek; Janusz H Piekarski; Piotr Potemski
Journal:  J Exp Clin Cancer Res       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.